Avedro Inc (AVDR) Gross Profit Margin starting from the third quarter 2019 to third quarter 2018, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket
 


Avedro Inc  (NASDAQ: AVDR)


Avedro Inc's Gross Profit Margin by quarter

Trends, Rankings, Statistics



AVDR Gross Profit Margin (Sep 30 2019)
Q3
(Jun 30 2019)
Q2
(Mar 31 2019)
Q1
(Sep 30 2018)
Q3
(Jun 30 2018)
Q2
Y / Y Revenue Change 75.47 %
Seq. Revenue Change 7.36 %
Revenue In Millions $11.05
Gross Profit Margin 78.24 %
Gross Profit Margin Total Ranking # 614
Gross Profit In Millions $8.64
Y / Y Gross Profit Change 143.37 %
Seq. Gross Profit Change 15.1 %


Commenting Third Quarter 2019 Gross Profit Margin
Avedro Inc Gross Profit grew by 15.1 % in Q3 sequentially to 9 millions, while Revenue increased by 7.36 %, this led to improvement in the company's Gross Profit Margin to 78.24 % a new company high.


Observing third quarter 2019 results within Major Pharmaceutical Preparations industry 73 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 614, from total ranking in the previous quarter at 805.
Learn about Gross Margin
AVDR's Gross Profit Margin third quarter 2019 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 74
Healthcare Sector # 132
Overall # 592

Gross Profit Margin Statistics
High Average Low
78.24 % 65.85 % 49.2 %
(Sep 30 2019)   (Mar 31 2018)




Other Gross Profit Margin Profitability Ratios
AVDR's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
AVDR's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for AVDR's Competitors
Gross Profit Margin Profit Margin for Avedro Inc's Suppliers
Gross Profit Margin Profit Margin for AVDR's Customers

You may also want to know
AVDR's Annual Growth Rates AVDR's Profitability Ratios AVDR's Asset Turnover Ratio AVDR's Dividend Growth
AVDR's Roe AVDR's Valuation Ratios AVDR's Financial Strength Ratios AVDR's Gross Profit Growth
AVDR's Roa AVDR's Inventory Turnover Ratio AVDR's Growth Rates AVDR's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2019, within Major Pharmaceutical Preparations Industry Gross Profit MarginSep 30 2019 MRQ Gross ProfitSep 30 2019 MRQ Revenue
Ayala Pharmaceuticals Inc   100.00 %$ 0.001  Millions$ 0.001  Millions
Lexicon Pharmaceuticals Inc   99.80 %$ 293.871  Millions$ 294.448  Millions
Nabriva Therapeutics Plc  99.78 %$ 6.905  Millions$ 6.920  Millions
Ironwood Pharmaceuticals inc   99.61 %$ 130.661  Millions$ 131.167  Millions
Ionis Pharmaceuticals Inc   99.42 %$ 166.925  Millions$ 167.892  Millions
Intercept Pharmaceuticals inc   99.21 %$ 61.463  Millions$ 61.950  Millions
Omeros Corporation  99.07 %$ 29.578  Millions$ 29.856  Millions
Rigel Pharmaceuticals Inc  98.51 %$ 20.547  Millions$ 20.857  Millions
Agios Pharmaceuticals Inc   98.49 %$ 25.631  Millions$ 26.024  Millions
Corcept Therapeutics Inc  98.22 %$ 80.054  Millions$ 81.505  Millions
Vaccinex Inc   98.02 %$ 0.396  Millions$ 0.404  Millions
Skinvisible Inc   97.79 %$ 0.011  Millions$ 0.011  Millions
Acadia Pharmaceuticals Inc   97.45 %$ 92.170  Millions$ 94.586  Millions
Emmaus Life Sciences Inc   97.07 %$ 5.906  Millions$ 6.084  Millions
Travere Therapeutics Inc   96.59 %$ 42.860  Millions$ 44.373  Millions
Celgene Corp  96.31 %$ 4,353.000  Millions$ 4,520.000  Millions
Sage Therapeutics Inc   96.16 %$ 3.433  Millions$ 3.570  Millions
Assertio Holdings inc   95.93 %$ 52.904  Millions$ 55.147  Millions
Ptc Therapeutics inc   95.79 %$ 68.410  Millions$ 71.416  Millions
Verastem Inc   95.66 %$ 8.640  Millions$ 9.032  Millions
Supernus Pharmaceuticals inc   95.28 %$ 97.321  Millions$ 102.140  Millions
Regeneron Pharmaceuticals Inc   94.34 %$ 1,932.500  Millions$ 2,048.400  Millions
Therapeuticsmd Inc   93.91 %$ 22.275  Millions$ 23.720  Millions
Adamas Pharmaceuticals Inc  93.33 %$ 13.004  Millions$ 13.933  Millions
Durect Corp  93.21 %$ 10.032  Millions$ 10.763  Millions
Portola Pharmaceuticals inc   92.71 %$ 34.115  Millions$ 36.799  Millions
Alnylam Pharmaceuticals Inc   92.56 %$ 64.848  Millions$ 70.061  Millions
Pfenex Inc   92.50 %$ 14.105  Millions$ 15.248  Millions
Alexion Pharmaceuticals Inc   92.46 %$ 1,167.900  Millions$ 1,263.100  Millions
Karyopharm Therapeutics Inc   92.30 %$ 12.136  Millions$ 13.149  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.